Physician profile
Beatriz Pendleton
NPI 1568082618
$9,565.82
in general payments reported to CMS, 2019-2025
31 companies · $807 in 2025
The $807 reported for 2025 was more than what a typical Neurology (Psychiatry & Neurology) provider received nationally (typical 2025 total: $454).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $13.15 · 2022: $858 · 2023: $1,456 · 2024: $6,432 · 2025: $807.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Grant: $5,000 · Food and Beverage: $3,695.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Grant | $5,000.00 |
| Food and Beverage | $3,694.66 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boston Scientific Corporation | $5,000.00 | 2024 | Vercise |
| Abbvie INC. | $512.91 | 2023-2025 | Botox |
| Csl Behring | $390.06 | 2022-2024 | Hizentra, Kcentra |
| Genentech USA, INC. | $383.52 | 2022-2024 | Evrysdi, Activase, Ocrevus |
| Ucb, INC. | $353.30 | 2023-2024 | Rystiggo, Briviact, Fintepla |
| Acadia Pharmaceuticals INC | $350.03 | 2024-2025 | Nuplazid, Daybue |
| Astrazeneca Pharmaceuticals LP | $232.69 | 2022-2024 | Andexxa |
| Amgen INC. | $217.17 | 2022-2023 | Repatha |
| Takeda Pharmaceuticals U.S.A., INC. | $191.89 | 2022-2024 | Hyqvia, Gammagard |
| Merz Pharmaceuticals, LLC | $156.22 | 2022-2025 | Xeomin, Inbrija |
| Genzyme Corporation | $151.11 | 2023-2024 | |
| Argenx US, INC. | $144.33 | 2022-2024 | Vyvgart, Vyvgart Hytrulo |
| Otsuka America Pharmaceutical, INC. | $141.39 | 2023 | Nuedexta |
| Alexion Pharmaceuticals, INC. | $133.46 | 2022-2025 | Ultomiris |
| Biogen, INC. | $132.21 | 2022-2024 | Vumerity, Tysabri |
Show all 31 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Globus Medical, INC. | $131.98 | 2025 | Senza, Vyrsa Fix |
| Medtronic, INC. | $130.72 | 2025 | Activa PC |
| Mdd US Operations, LLC | $119.43 | 2025 | Gocovri |
| Eisai INC. | $108.24 | 2023-2024 | |
| Amneal Pharmaceuticals LLC | $105.83 | 2024-2025 | Crexont |
| Novartis Pharmaceuticals Corporation | $100.60 | 2024 | |
| Pfizer INC. | $70.24 | 2021-2023 | |
| Biohaven Pharmaceutical Holding Company LTD. | $67.51 | 2022 | |
| Emd Serono, INC. | $56.13 | 2022-2023 | Mavenclad |
| Tanabe Pharma America, INC. | $44.78 | 2023 | |
| Esperion Therapeutics, INC. | $40.81 | 2022-2023 | Nexletol |
| Kyowa Kirin, INC. | $23.36 | 2025 | |
| Neurelis, INC. | $23.27 | 2023 | Valtoco |
| Cala Health, INC. | $20.80 | 2024 | Cala Trio, Cala Kiq |
| Azurity Pharmaceuticals, INC. | $18.66 | 2024 | Horizant |
| Grifols USA, LLC | $13.17 | 2023 | Gamunex-C |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Beatriz Pendleton listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.